Your browser doesn't support javascript.
loading
Effectiveness of an Inactivated Covid-19 Vaccine with Homologous and Heterologous Boosters against the Omicron (B.1.1.529) Variant
Otavio T. Ranzani; Matt Hitchings; Rosana Leite de Melo; Giovanny V. A. de França; Cássia de Fátima R. Fernandes; Margaret Lind; Mario Sergio Scaramuzzini Torres; Daniel Henrique Tsuha; Leticia C. S. David; Rodrigo F. C. Said; Maria Almiron; Roberto D. de Oliveira; Derek A.T. Cummings; Natalie E. Dean; Jason R. Andrews; Albert I. Ko; Julio Croda.
Afiliação
  • Otavio T. Ranzani; Barcelona Institute for Global Health, ISGlobal, UPF, CIBERESP, Spain / Pulmonary Division, University of Sao Paulo
  • Matt Hitchings; Department of Biostatistics, College of Public Health & Health Professions, University of Florida, Gainesville, FL, USA
  • Rosana Leite de Melo; Secretaria Extraordinaria de Enfrentamento a Covid-19, Ministerio da Saude, Brasilia, DF, Brazil
  • Giovanny V. A. de França; Secretaria de Vigilancia em Saude, Ministerio da Saude, Brasilia, DF, Brazil
  • Cássia de Fátima R. Fernandes; Secretaria de Vigilancia em Saude, Ministerio da Saude, Brasilia, DF, Brasil
  • Margaret Lind; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA
  • Mario Sergio Scaramuzzini Torres; Municipal Health Secretary of Manaus, AM, Brazil
  • Daniel Henrique Tsuha; Fiocruz Mato Grosso do Sul, Fundacao Oswaldo Cruz, Campo Grande, MS, Brazil
  • Leticia C. S. David; Pan American Health Organization, Brasilia, DF, Brazil
  • Rodrigo F. C. Said; Pan American Health Organization, Brasilia, DF, Brazil
  • Maria Almiron; Pan American Health Organization, Brasilia, DF, Brazil
  • Roberto D. de Oliveira; Fiocruz Mato Grosso do Sul, Fundacao Oswaldo Cruz, Campo Grande, MS, Brazil / State University of Mato Grosso do Sul, Dourados, MS, Brazil
  • Derek A.T. Cummings; Department of Biology, University of Florida, Gainesville, FL, USA / Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA
  • Natalie E. Dean; Department of Biostatistics & Bioinformatics, Rollins School of Public Health, Emory University
  • Jason R. Andrews; Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, CA, USA
  • Albert I. Ko; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA / Instituto Goncalo Moniz, Fundacao Oswaldo Cruz, Salvador, B
  • Julio Croda; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA / Fiocruz Mato Grosso do Sul, Fundacao Oswaldo Cruz, Campo Gr
Preprint em Inglês | medRxiv | ID: ppmedrxiv-22273193
ABSTRACT
The effectiveness of inactivated vaccines (VE) against symptomatic and severe COVID-19 caused by omicron is unknown. We conducted a nationwide, test-negative, case-control study to estimate VE for homologous and heterologous (BNT162b2) booster doses in adults who received two doses of CoronaVac in Brazil in the Omicron context. Analyzing 1,386,544 matched-pairs, VE against symptomatic disease was 8.6% (95% CI, 5.6-11.5) and 56.8% (95% CI, 56.3-57.3) in the period 8-59 days after receiving a homologous and heterologous booster, respectively. During the same interval, VE against severe Covid-19 was 73.6% (95% CI, 63.9-80.7) and 86.0% (95% CI, 84.5-87.4) after receiving a homologous and heterologous booster, respectively. Waning against severe Covid-19 after 120 days was only observed after a homologous booster. Heterologous booster might be preferable to individuals with completed primary series inactivated vaccine.
Licença
cc_by_nc_nd
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Experimental_studies / Estudo observacional Idioma: Inglês Ano de publicação: 2022 Tipo de documento: Preprint
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Experimental_studies / Estudo observacional Idioma: Inglês Ano de publicação: 2022 Tipo de documento: Preprint
...